Table 5.

Patient characteristics according to PD‐L1 expression and FGFR 1–3 aberrations in primary tumor tissue

Patient nr.	Age	Gender	Primary tumor	Stage	Histology	PD‐L1 CPS score	FGFR 1 1–3 aberrations
							FGFR1 aberrations
1.	69	M	Bladder	pT2	UC NOS	0.5	Mutation p.D585H
							FGFR2 aberrations
2.	64	M	Bladder	pT2	UC NOS	10.0	FGFR2 amplification (copies 16)
3.	75	M	Bladder	pT2	UC DHD 2	5.5	Mutation H254Y
							FGFR3 aberrations
4.	63	F	Bladder	pT1	UC NOS	1.9	Mutation p.G370C
5.	59	M	Bladder	pT2	UC NOS	1.4	FGFR3 amplification (copies 10) and Mutation p.Y373C
6.	71	M	Bladder	pT2	UC NOS	11.2	FGFR3 amplification (copies 9)
7.	56	F	Bladder	pT2	UC SD 3	13.1	FGFR3 amplification (copies 5)
8.	53	F	Renal pelvis	pT4	UC NOS	0.1	FGFR3 amplification (copies 33)
9.	73	M	Bladder	pT2	UC NOS	0.5	FGFR3 amplification (copies 23)
10.	66	M	Renal pelvis	pT4	UC NOS	4.6	FGFR3 amplification (copies 9) FGFR1 amplification (copies 6)
11.	69	M	Renal pelvis	pT3	UC NOS	0	FGFR3 amplification (copies 14)
12.	69	M	Ureter	pT3	UC NOS	4.4	FGFR3 amplification (copies 5)
13.	61	M	Bladder	pT1b	UC NOS	5.4	Mutation p.R248C
14.	62	M	Bladder	pT2b	UC DHD 2	4.5	Mutation p.S249C
15.	52	F	Renal pelvis	pT4	UC DHD 2	0.4	Mutation p.R248C
16.	81	F	Bladder	pT2	UC NOS	1.9	Mutation p.Y373C
17.	71	M	Bladder	pT1	UC NOS	0.2	Mutation p.Y373C

¹ Fibroblast growth factor receptor.

² UC DHD, Urothelial carcinoma with divergent histological differentiation.

³ UC SD, Urothelial carcinoma with squamous differentiation.